Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
about
Aldosterone antagonists for preventing the progression of chronic kidney diseaseImpact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsCharacterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats.Eplerenone for the treatment of cardiovascular disorders.Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.Drug-induced hyperkalemia.Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.Is Entresto good for the brain?Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor.Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?Genomic and rapid effects of aldosterone: what we know and do not know thus far.Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor.Hypercapnic Chemosensitivity in Patients with Heart Failure: Relation to Shifts in Type-1 Insulin-Like Growth Factor and Sex Hormone-Binding Globulin Levels
P2860
Q24194979-7C6BDACA-1360-4906-8D87-442C57F53F94Q26764927-8643583A-3D79-4537-9583-95F59F116B83Q35034941-BF3C1A32-B118-445C-AF0B-890AA2F5AC5AQ38036328-F120CA38-A526-4767-94F5-804E0B3A7D0CQ38123754-8643B69B-907D-4863-8D8E-B08DBE812264Q38232308-5BF04714-E8AB-4982-9573-F259C54B58B8Q38382574-D37167CE-95F8-4D66-8800-83BFC498C8CDQ41264931-67240CE4-E97E-49E9-AC78-46EB53DCDF2CQ41714003-AF88DCB9-9D61-4F01-9504-DC9ED6F00E05Q42776028-BD022FCE-550B-4FE6-B174-EB4517576B2FQ50876472-47AC8123-8F31-4001-86E3-5599E9298A10Q51273122-7C0D985B-8CE2-412F-AE05-28BA41F86D5EQ54263200-0BA521C6-3866-4521-B654-0E4EB47404E0Q54969723-6A641998-884A-4A70-957F-9AEB463CCF75Q57911425-BC8ED25B-2000-457B-9A91-D526D0C0FAFB
P2860
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
@en
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
@nl
type
label
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
@en
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
@nl
prefLabel
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
@en
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
@nl
P2860
P921
P356
P1476
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
@en
P2093
Jean M Nappi
P2860
P304
P356
10.2147/VHRM.S13779
P407
P577
2011-06-08T00:00:00Z